Date Insider Type Main position Quantity % Market Cap. Importance
23/10/23 Free

General Counsel

70,000 0.7479%
16/10/23 Free

Chief Financial Officer

151,416 1.6178%
15/09/23
Versi Group LLC
ConversionCompany 729,200 7.7913%
Change 5-day change 1-year change 3-year change Capi.($)
-99.00%-99.00% - - 10
+0.01%-2.47%+57.79%+108.23% 1,034B
+1.48%+1.93%+54.56%+71.49% 663B
+0.67%-0.45%+23.50%+76.60% 462B
+1.65%-2.53%+31.65%+37.71% 344B
-0.19%+5.23%+27.24%+47.32% 307B
+1.34%+0.18%-0.61%+13.53% 251B
+1.08%+0.57%+54.34%+72.51% 239B
+1.39%+3.64%-16.08%-53.31% 207B
-0.21%+1.03%+32.74%+95.19% 186B
Average -9.47%-0.70%+29.46%+52.14% 410.37B
Weighted average by Cap. +0.45%-0.84%+38.36%+67.59%
Logo DMK Pharmaceuticals Corporation
DMK Pharmaceuticals Corporation is a commercial stage neuro-biotech company. The Company is focused on developing and commercializing products for the treatment of opioid overdose and substance-use disorders. Its ZIMHI (naloxone) is FDA approved for the treatment of opioid overdose. It is focused on developing novel therapies for opioid use disorder (OUD) and other important neuro-based conditions where patients are currently underserved. Its technologies are at the forefront of endorphin-inspired drug design with its mono, bi-, and tri-functional small molecules that simultaneously modulate critical networks in the nervous system. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. Its other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
Employees
12
  1. Stock Market
  2. Stocks
  3. DMKPQ Stock